

Supplementary Information




Fig. S1. A. The cell viability of indicated cells treated with PAT delivered with different ratios of DNCA to CLD after 48 h. **B.** The cell viability of indicated cells treated with empty Mix lipids at different ratios. PAT, 1 mg/ml.




Fig. S2. RT-qPCR analysis of SLIT3, GCLC and PCLAF mRNA in A549 cells treated with indicated formulations for 24 h (PAT, 1 mg/mL; DNCA/CLD, 10/10 μg/ml).




Fig. S3. Principal component analysis of the protein expression data for all samples.




Fig. S4. Principal component analysis of the gene expression data for all samples.




Fig. S5. GO annotation analysis of differentially expressed proteins in A549 cells (PAT/Mix vs Mix).




Fig. S6. GO annotation analysis of differentially expressed genes in A549 cells (PAT/Mix vs Mix).




Fig. S7. The top 20 enrichment KEGG pathways in A549 cells are displayed in the senior bubble chart (PAT/Mix vs Mix).




Fig. S8. Scatter plot for GO term enrichment analysis of top 30 differentially expressed genes in A549 cells.